158 related articles for article (PubMed ID: 36326247)
21. Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease.
Jhun BW; Moon SM; Kim SY; Park HY; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Chung MJ; Lee KS; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203483
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease.
Lee BY; Kim S; Hong Y; Lee SD; Kim WS; Kim DS; Shim TS; Jo KW
Antimicrob Agents Chemother; 2015; 59(6):2972-7. PubMed ID: 25753634
[TBL] [Abstract][Full Text] [Related]
23. Different clinical features of patients with pulmonary disease caused by various Mycobacterium avium-intracellulare complex subspecies and antimicrobial susceptibility.
Chang CL; Chen LC; Yu CJ; Hsueh PR; Chien JY
Int J Infect Dis; 2020 Sep; 98():33-40. PubMed ID: 32534139
[TBL] [Abstract][Full Text] [Related]
24. Antibiotic Maintenance and Redevelopment of Nontuberculous Mycobacteria Pulmonary Disease after Treatment of Mycobacterium avium Complex Pulmonary Disease.
Zo S; Kim H; Kwon OJ; Jhun BW
Microbiol Spectr; 2022 Aug; 10(4):e0108822. PubMed ID: 35950873
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis.
Park Y; Lee EH; Jung I; Park G; Kang YA
Respir Res; 2019 Dec; 20(1):286. PubMed ID: 31852452
[TBL] [Abstract][Full Text] [Related]
26. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.
Mehta RT
Antimicrob Agents Chemother; 1996 Aug; 40(8):1893-902. PubMed ID: 8843300
[TBL] [Abstract][Full Text] [Related]
27. Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients.
Ramirez J; Mason C; Ali J; Lopez FA
J La State Med Soc; 2008; 160(5):248-54; quiz 254, 293. PubMed ID: 19048978
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Prognosis and Antimycobacterial Glycolipid Antibody as Biomarker in Mycobacterium avium-intracellulare Complex Pulmonary Disease.
Maekura R; Miki K; Tateishi Y; Matsumoto S; Kitada S; Miki M; Kida H
Microbiol Spectr; 2022 Jun; 10(3):e0053022. PubMed ID: 35467367
[TBL] [Abstract][Full Text] [Related]
29. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen.
Koh WJ; Hong G; Kim SY; Jeong BH; Park HY; Jeon K; Kwon OJ; Lee SH; Kim CK; Shin SJ
Antimicrob Agents Chemother; 2013 May; 57(5):2281-5. PubMed ID: 23478956
[TBL] [Abstract][Full Text] [Related]
30. Treatment outcomes of the interstitial lung disease subtype of unclassifiable type Mycobacterium avium complex pulmonary disease.
Park YE; Lee JH; Chong YP; Lee HJ; Kim HC; Song JW; Shim TS; Jo KW
J Infect Chemother; 2022 Aug; 28(8):1112-1118. PubMed ID: 35400550
[TBL] [Abstract][Full Text] [Related]
31. Difference in drug susceptibility distribution and clinical characteristics between
Wang W; Yang J; Wu X; Wan B; Wang H; Yu F; Guo Y
J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
[No Abstract] [Full Text] [Related]
32. Treatment of Mycobacterium avium Complex (MAC).
Griffith DE
Semin Respir Crit Care Med; 2018 Jun; 39(3):351-361. PubMed ID: 30071550
[No Abstract] [Full Text] [Related]
33. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.
Jeong BH; Jeon K; Park HY; Kim SY; Lee KS; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Am J Respir Crit Care Med; 2015 Jan; 191(1):96-103. PubMed ID: 25393520
[TBL] [Abstract][Full Text] [Related]
34. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.
Zweijpfenning S; Kops S; Magis-Escurra C; Boeree MJ; van Ingen J; Hoefsloot W
Respir Med; 2017 Oct; 131():220-224. PubMed ID: 28947034
[TBL] [Abstract][Full Text] [Related]
35. Long-term radiographic outcome of nodular bronchiectatic Mycobacterium avium complex pulmonary disease.
Kitada S; Uenami T; Yoshimura K; Tateishi Y; Miki K; Miki M; Hashimoto H; Fujikawa T; Mori M; Matsuura K; Kuroyama M; Maekura R
Int J Tuberc Lung Dis; 2012 May; 16(5):660-4. PubMed ID: 22410245
[TBL] [Abstract][Full Text] [Related]
36. Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease.
Moon SM; Kim SY; Kim DH; Huh HJ; Lee NY; Jhun BW
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0202721. PubMed ID: 35266825
[TBL] [Abstract][Full Text] [Related]
37. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.
Kadota T; Matsui H; Hirose T; Suzuki J; Saito M; Akaba T; Kobayashi K; Akashi S; Kawashima M; Tamura A; Nagai H; Akagawa S; Kobayashi N; Ohta K
BMC Infect Dis; 2016 Jan; 16():31. PubMed ID: 26818764
[TBL] [Abstract][Full Text] [Related]
38. Treatment strategies with alternative treatment options for patients with Mycobacterium avium complex pulmonary disease.
Ito M; Koga Y; Hachisu Y; Murata K; Sunaga N; Maeno T; Hisada T
Respir Investig; 2022 Sep; 60(5):613-624. PubMed ID: 35781424
[TBL] [Abstract][Full Text] [Related]
39. Radiologic Subtypes and Treatment Outcome of Unclassifiable Type
Lee JH; Park YE; Chong YP; Lee HJ; Shim TS; Jo KW
J Korean Med Sci; 2023 Jan; 38(3):e16. PubMed ID: 36647217
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes in Mycobacterium xenopi versus Mycobacterium avium complex pulmonary disease: A retrospective matched cohort study.
Zaheen A; Hirama T; Mehrabi M; Brode SK; Marras TK
Respir Med; 2020 Jun; 167():105967. PubMed ID: 32421543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
